Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec - PubMed (original) (raw)
. 2005 Nov 1;41(9):1254-60.
doi: 10.1086/496986. Epub 2005 Sep 20.
Nathalie Saheb, Marie-Andrée Coulombe, Marie-Eve Alary, Marie-Pier Corriveau, Simon Authier, Michel Leblanc, Geneviève Rivard, Mathieu Bettez, Valérie Primeau, Martin Nguyen, Claude-Emilie Jacob, Luc Lanthier
Affiliations
- PMID: 16206099
- DOI: 10.1086/496986
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec
Jacques Pépin et al. Clin Infect Dis. 2005.
Abstract
Background: Since 2002, an epidemic of Clostridium difficile-associated-diarrhea (CDAD) associated with a high case-fatality rate has involved >30 hospitals in the province of Quebec, Canada. In 2003, a total of 55% of patients with CDAD at our hospital had received fluoroquinolones in the preceding 2 months. It has been suggested that massive use of proton pump inhibitors might have facilitated this epidemic.
Methods: To delineate the risk of CDAD associated with specific classes of antibiotics and whether this is modulated by concomitant use of proton pump inhibitors and other drugs altering gastric acidity or gastrointestinal motility, we conducted a retrospective cohort study of patients hospitalized in a teaching hospital in Sherbrooke, Canada, during the period of January 2003 through June 2004. We obtained data on 7421 episodes of care corresponding to 5619 individuals. Patients were observed until they either developed CDAD or died or for 60 days after discharge from the hospital. Adjusted hazard ratios (AHRs) were calculated using Cox regression.
Results: CDAD occurred in 293 patients. Fluoroquinolones were the antibiotics most strongly associated with CDAD (AHR, 3.44; 95% confidence interval [CI], 2.65-4.47). Almost one-fourth of all inpatients received quinolones, for which the population-attributable fraction of CDAD was 35.9%. All 3 generations of cephalosporins, macrolides, clindamycin, and intravenous beta-lactam/beta-lactamase inhibitors were intermediate-risk antibiotics, with similar AHRs (1.56-1.89). Proton pump inhibitors (AHR, 1.00, 95% CI, 0.79-1.28) were not associated with CDAD.
Conclusions: Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.
Comment in
- Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec.
Weiss K. Weiss K. Clin Infect Dis. 2006 Mar 1;42(5):725-7; author reply 727-9. doi: 10.1086/500268. Clin Infect Dis. 2006. PMID: 16447121 No abstract available. - Clostridium difficile-associated diarrhea outbreaks: the name of the game is isolation and cleaning.
Beaulieu M, Thirion DJ, Williamson D, Pichette G. Beaulieu M, et al. Clin Infect Dis. 2006 Mar 1;42(5):725; author reply 727-9. doi: 10.1086/500264. Clin Infect Dis. 2006. PMID: 16447122 No abstract available.
Similar articles
- Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M, Schroeder T, Kramer J, Zackula R. Aseeri M, et al. Am J Gastroenterol. 2008 Sep;103(9):2308-13. doi: 10.1111/j.1572-0241.2008.01975.x. Epub 2008 Aug 12. Am J Gastroenterol. 2008. PMID: 18702653 - A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.
Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, Thompson A, Jensen B, Wiggs L, Bessette J, Martin J, Clukey J, Gensheimer K, Killgore G, McDonald LC. Kazakova SV, et al. Arch Intern Med. 2006 Dec 11-25;166(22):2518-24. doi: 10.1001/archinte.166.22.2518. Arch Intern Med. 2006. PMID: 17159019 - Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.
Pépin J, Routhier S, Gagnon S, Brazeau I. Pépin J, et al. Clin Infect Dis. 2006 Mar 15;42(6):758-64. doi: 10.1086/501126. Epub 2006 Feb 7. Clin Infect Dis. 2006. PMID: 16477549 - Established and potential risk factors for Clostridum difficile infection.
Vaishnavi C. Vaishnavi C. Indian J Med Microbiol. 2009 Oct-Dec;27(4):289-300. doi: 10.4103/0255-0857.55436. Indian J Med Microbiol. 2009. PMID: 19736396 Review.
Cited by
- Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Clostridioides difficile Infection.
Zaidi SMH, Haider R, Kazmi SAB, Husnain A, Khan S, Merchant S, Tayyab H, Wazeen FR, Chaudhary AJ. Zaidi SMH, et al. ACG Case Rep J. 2024 Jul 27;11(8):e01333. doi: 10.14309/crj.0000000000001333. eCollection 2024 Aug. ACG Case Rep J. 2024. PMID: 39081300 Free PMC article. No abstract available. - Delabelling beta-lactam allergy.
Molina-Molina GJ, Garnica Velandia DR, Andrés-López B, Perales C, Marin-Asensio L, Jurgens Y, Esteso O, Escobar C, Vidal X, Vendrell L, Gómez-Ganda L, Rodríguez D, Montané E, Cardona V, Agustí A. Molina-Molina GJ, et al. Front Pharmacol. 2024 Jun 27;15:1423719. doi: 10.3389/fphar.2024.1423719. eCollection 2024. Front Pharmacol. 2024. PMID: 38994200 Free PMC article. - The changing epidemiology of Clostridioides difficile infection and the NAP1/027 strain in two Québec hospitals: a 17-year time-series study.
Couture S, Frenette C, Schiller I, Alfaro R, Dendukuri N, Thirion D, Longtin Y, Loo VG. Couture S, et al. Antimicrob Steward Healthc Epidemiol. 2024 Jun 4;4(1):e99. doi: 10.1017/ash.2024.95. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38836044 Free PMC article. - Toxin genotypes, antibiotic resistance and their correlations in Clostridioides difficile isolated from hospitals in Xi'an, China.
Zhang S, Ma C, Zhang H, Zhao C, Guo R, Liu J, Wang J, Yuan J, Jia K, Wu A, Chen Y, Lei J. Zhang S, et al. BMC Microbiol. 2024 May 23;24(1):177. doi: 10.1186/s12866-024-03327-z. BMC Microbiol. 2024. PMID: 38783194 Free PMC article. - Oral β-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Uncomplicated Escherichia coli or Klebsiella Species Bacteremia From a Urinary Tract Source.
Alzaidi S, Veillette JJ, May SS, Olson J, Jackson K, Waters CD, Butler AM, Hutton MA, Buckel WR, Webb BJ. Alzaidi S, et al. Open Forum Infect Dis. 2023 Dec 27;11(2):ofad657. doi: 10.1093/ofid/ofad657. eCollection 2024 Feb. Open Forum Infect Dis. 2023. PMID: 38370295 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical